INNOVATE
Lyonbiopole's thematics
The cluster’s R&D domains
The cluster is structuring around two programs
> Diagnostic
> Vaccines and new biotherapies
The cluster’s domains are: infectious diseases, cancers, virology, bacteriology, parasitology, mycology, immunology and immune disorders, including those relating to autoimmune, inflammatory and orphans diseases.
The diagnostic program for molecular and cell diagnostics: It includes projects in the development of multiparameter testing of DNA / RNA detection, laboratory "on chip" automation, the biological exploration of new pathogens and their detection, the study of infectious diseases and the identification of their prognostic markers and their predictors.
The vaccines and new biotherapies programs aims to :
- develop prophylactic vaccines for the emerging and reemerging diseases and pandemics such as avian flu or dengue fever’s prevention, and new therapeutic approaches in order to specialize treatment for chronic infectious diseases (type hepatitis C)
- optimize treatment while working on delivery modes, the active ingredients potentiation and their vectorization
- strengthen prevention and treatment means to respond specifically to the patient‘s needs
Lyonbiopôle also works on the development of technological tools (interactome, micro-nano technology, protein expression, optimizing system-molecule ,vectorology, vaccinomics or ex vivo screening, cell biology and culture media, structural biology).
These technological tools are designed to provide new approaches to :
> transfer them directly into projects
> make available key technologies for programs that answer the compagnies’ needs, creating physical resources and pooling of equipment and personnel
The cluster’s focuses – Download (PDF)
They speak about...
« By helping academic and industrial partners work more closely together, Lyonbiopole is a true catalyst in the emergence and setup of large-scale innovative R&D projects. iDD biotech has two projects accredited by the cluster (PRAVIC & GLIADYS), which are key steps in the development of an SMB. The cluster’s support, through its professionalism and dynamism, enables us to speed up the development of biotech-based candidate medicines, by integrating a number of technological building blocks that rely on local expertise. This is a means to boost players in various sectors – private or public – by pooling everyone’s expertise and know-how, while making the local and national economy more competitive. »
Claudine Vermot-Desroches
iDD-Biotech - Director of R&D